Sharesource Connectivity Platform for Use with Homechoice Claria Product Code 5CGM01 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM) Recall
Sharesource Connectivity Platform for Use with Homechoice Claria Product Code 5CGM01 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM)
FDA recall Class II
Ongoing
FDA lists this Class II recall for Sharesource Connectivity Platform for Use with Homechoice Claria Product Code 5CGM01 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM). Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-0409-2026
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Aug 28, 2025
- FDA report date
- Nov 5, 2025
- Quantity in commerce
- 1
- Distribution
- See key details
- FDA cause
- Software design
What is being recalled?
Sharesource Connectivity Platform for Use with Homechoice Claria Product Code 5CGM01 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM)
Affected model & UDI checker
Search the exact identifiers published for Z-0409-2026.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| Not specified | Sharesource Connectivity Platform for Use with Homechoice Claria Product Code 5CGM01 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM) | Check source notice | 15413765545723 |
FDA code information
UDI-DI 15413765545723 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM)
Why was this product recalled?
Vantive has identified a software defect within the Sharesource Claria software, which may cause a patient s updated prescription program settings to not be properly saved on the actual cycler that the patient is using to perform their therapy. As a result, the clinician may think that the patient is receiving the correct prescribed therapy because of what is erroneously displayed on the clinician's remote Sharesource application, when in fact the cycler that is with the patient is actually delivering an outdated and incorrect therapy.
What actions did Vantive US Healthcare, LLC take?
Clinics whose patients' programs were identified as being impacted by this issue were contacted by phone beginning 8/29/2025. Follow-up written notifications were sent out to all affected customers starting September 11, 2025. The Sharesource Claria software fix has been deployed and no further actions need to be taken by facilities who did not have directly affected patients. Note: If you have received the previous direct notification regarding a patient at your clinic, please note that Vantive will continue to be in touch with you regarding the next steps to correct those specific patient programs.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-0409-2026
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 21, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 21, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology